Bioventus Inc. (BVS): Price and Financial Metrics

Bioventus Inc. (BVS): $6.38

0.16 (-2.45%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

BVS Price/Volume Stats

Current price $6.38 52-week high $7.04
Prev. close $6.54 52-week low $2.70
Day low $6.35 Volume 252,800
Day high $6.58 Avg. volume 221,089
50-day MA $5.48 Dividend yield N/A
200-day MA $4.56 Market Cap 505.08M

BVS Stock Price Chart Interactive Chart >


Bioventus Inc. (BVS) Company Bio


Bioventus Inc. focuses on operating as a holding company for Bioventus LLC that operates as a medical device company. It develops and commercializes clinically treatments that engage and enhance the body's natural healing process in the United States and internationally. The company provides osteoarthritic joint pain treatment and joint preservation products, including Durolane, a single injection therapy; GELSYN-3, a three injection therapy; and SUPARTZ FX, a five injection therapy. It also offers bone graft substitutes comprising allograft-derived bone graft with growth factors, demineralized bone matrix, cancellous bone in different preparations, bioactive synthetics, collagen ceramic matrix, and bone marrow isolation systems. In addition, the company provides Exogen systems for the non-invasive treatment of established nonunion fractures and certain fresh fractures. It serves physicians spanning the orthopedic continuum, including sports medicine, total joint reconstruction, hand and upper extremities, foot and ankle, podiatric surgery, trauma, spine, and neurosurgery in the physician's office or clinic, ambulatory surgical centers, or in the hospital setting. The company was founded in 2011 and is based in Durham, North Carolina.


BVS Latest News Stream


Event/Time News Detail
Loading, please wait...

BVS Latest Social Stream


Loading social stream, please wait...

View Full BVS Social Stream

Latest BVS News From Around the Web

Below are the latest news stories about BIOVENTUS INC that investors may wish to consider to help them evaluate BVS as an investment opportunity.

Bioventus Names Robert Claypoole as President and Chief Executive Officer

Seasoned Leader Brings More than Two Decades of Medical Device Experience and Proven Track Record of Driving Revenue and Operating Margin GrowthDURHAM, N.C., Dec. 19, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that its Board of Directors has appointed Robert (Rob) Claypoole as Bioventus’ President and Chief Executive Officer and a member of its Board of Directors, effective January 10, 2

Yahoo | December 19, 2023

Bioventus Agrees to Nationwide Contract with Aetna™ Medicare Advantage Plans for DUROLANE® for Knee Osteoarthritis

DURHAM, N.C., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has agreed to a nationwide contract with Aetna™ Medicare Advantage plans. Beginning January 1, 2024, over 3 million Aetna™ Medicare Advantage plan members will have access to DUROLANE to treat knee osteoarthritis (OA) pain. DUROLANE, is a single-injection hyaluronic acid (HA)-based joint-fluid treatment for patients. DUROLANE will be one

Yahoo | December 6, 2023

Smith & Nephew inks $180M CartiHeal buyout, capitalizing on Bioventus turmoil to land knee implant

Bioventus’ protracted buyout bid ultimately fell apart and opened the door to Smith & Nephew.

Yahoo | November 27, 2023

Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript

Bioventus Inc. (NASDAQ:BVS) Q3 2023 Earnings Call Transcript November 12, 2023 Operator: Thank you for standing by. My name is Dustin, and I will be your conference operator today. This time, I would like to welcome everyone to Bioventus Inc. Third Quarter 2023 Earnings Conference Call. [Operator Instructions] At this time, I’d like to turn […]

Yahoo | November 12, 2023

Bioventus Inc (BVS) Reports Q3 2023 Financial Results, Raises Full Year 2023 Financial Guidance

Despite a decrease in net sales, the company's financial results exceeded expectations with improved performance in Pain Treatments and continued cost management

Yahoo | November 7, 2023

Read More 'BVS' Stories Here

BVS Price Returns

1-mo 0.00%
3-mo 18.15%
6-mo 22.46%
1-year 101.58%
3-year -63.65%
5-year N/A
YTD 21.06%
2023 101.92%
2022 -81.99%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!